Related Experiment Video
Updated: Jul 15, 2025
05:25
Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies
Published on: December 29, 2021
2.6K
Cannabidiol and Intestinal Motility: a Systematic Review
Galaxie Story1, Carrie-Ellen Briere2, D Julian McClements1
1Department of Food Science, University of Massachusetts, Amherst, MA, United States.
Current Developments in Nutrition
|October 3, 2023
Summary
Cannabidiol (CBD) shows potential for gastrointestinal disorders, with promising preclinical data on intestinal motility. However, more clinical research is needed to establish its efficacy and optimal dosing for these conditions.
Area of Science:
- Pharmacology
- Gastroenterology
- Cannabinoid research
Background:
- Cannabidiol (CBD) is a non-intoxicating cannabinoid with claimed medicinal benefits.
- Evidence substantiating CBD's efficacy for gastrointestinal (GI) disorders is currently limited.
- Consumer use of CBD for GI issues is increasing due to availability and acceptance.
Purpose of the Study:
- To systematically review the existing research on CBD, intestinal motility, and related disorders.
- To evaluate the current knowledge boundaries regarding CBD's effects on the GI system.
- To assess the therapeutic potential of CBD for functional gastrointestinal disorders.
Main Methods:
- Systematic literature review of published research.
- Evaluation of in vitro and preclinical studies on CBD and intestinal motility.
- Analysis of available clinical trial data on CBD for GI motility disorders.
Main Results:
- Preclinical data suggest CBD may positively influence intestinal motility, including in models of colitis.
- CBD has demonstrated safety and efficacy in other therapeutic areas like seizure disorders and nausea/vomiting.
- Clinical trials investigating CBD for intestinal motility disorders are limited and have not yet shown conclusive benefits.
Conclusions:
- CBD shows promise for functional gastrointestinal disorders based on in vitro and preclinical findings.
- Significant variability exists in study designs, including CBD dosage and extract composition.
- Further rigorous clinical trials are necessary to determine CBD's efficacy, optimal dosing, and specific applications for intestinal motility disorders.
Related Concept Videos
01:17Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
230
Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
230
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
367
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
367
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
289
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
289
01:20Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
237
Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
Adsorbents...
237
01:20Drugs Affecting GI Tract Motility: Other Laxatives
256
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
256
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
300
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
300